-
公开(公告)号：US08840913B2
公开(公告)日：2014-09-23
申请号：US12056549
申请日：2008-03-27
申请人： William F. McKay , Jeffrey L. Scifert , Kathy L. Remsen , Didier Billy , Mirian Gillissen , Scott M. Vickers
发明人： William F. McKay , Jeffrey L. Scifert , Kathy L. Remsen , Didier Billy , Mirian Gillissen , Scott M. Vickers
CPC分类号： A61K38/1875 , A61K9/0024 , A61L27/26 , A61L27/54 , A61L2300/414 , A61L2430/02 , C08L5/04 , C08L89/06
摘要： Described are implantable, malleable medical materials comprising mineral particles, insoluble collagen fibers, and a gel-forming polysaccharide component and/or another added gel-former. The malleable medical materials can be used treat bone or other tissue defects in patients, including in conjunction with biologically active factors such as osteogenic proteins. Also described are methods and materials that can be used to prepare the malleable medical materials.
摘要翻译： 描述了包括矿物颗粒，不溶性胶原纤维和形成凝胶的多糖组分和/或另外添加的凝胶形成剂的可植入的可延展的医用材料。 可延展的医疗材料可用于治疗患者的骨骼或其他组织缺陷，包括结合生物活性因子如成骨蛋白。 还描述了可用于制备可延展的医疗材料的方法和材料。
-
公开(公告)号：US09364582B2
公开(公告)日：2016-06-14
申请号：US13238844
申请日：2011-09-21
CPC分类号： A61L27/20 , A61F2/28 , A61L27/24 , A61L27/3608 , A61L27/365 , A61L27/48
摘要： Described are malleable medical compositions such as pastes or putties that include solids combined with a liquid carrier. The solids can include particulate collagen and particulate demineralized bone matrix. The liquid carrier includes an aqueous medium comprising one or more polysaccharides. Also described are methods for making and using such medical compositions.
摘要翻译： 描述的是可延展的药物组合物，例如包括与液体载体结合的固体的糊剂或油灰。 固体可以包括颗粒胶原和颗粒脱矿质骨基质。 液体载体包括含有一种或多种多糖的水性介质。 还描述了制备和使用这种医药组合物的方法。
-
公开(公告)号：US20120009230A1
公开(公告)日：2012-01-12
申请号：US13238844
申请日：2011-09-21
CPC分类号： A61L27/20 , A61F2/28 , A61L27/24 , A61L27/3608 , A61L27/365 , A61L27/48
摘要： Described are malleable medical compositions such as pastes or putties that include solids combined with a liquid carrier. The solids can include particulate collagen and particulate demineralized bone matrix. The liquid carrier includes an aqueous medium comprising one or more polysaccharides. Also described are methods for making and using such medical compositions.
摘要翻译： 描述的是可延展的药物组合物，例如包括与液体载体结合的固体的糊剂或油灰。 固体可以包括颗粒胶原和颗粒脱矿质骨基质。 液体载体包括含有一种或多种多糖的水性介质。 还描述了制备和使用这种医药组合物的方法。
-
公开(公告)号：US20090263444A1
公开(公告)日：2009-10-22
申请号：US12413197
申请日：2009-03-27
申请人： William F. McKay , Christopher M. Hobot , Danielle Biggs , Katara Shaw , John Myers Zanella , Vanja M. King , Stephen Mark Cox , Kathy L. Remsen
发明人： William F. McKay , Christopher M. Hobot , Danielle Biggs , Katara Shaw , John Myers Zanella , Vanja M. King , Stephen Mark Cox , Kathy L. Remsen
CPC分类号： A61K31/58 , A61K9/0024 , A61K9/1647 , A61K31/585 , A61K47/34
摘要： Effective treatments of pain and inflammation are provided. Through the administration of an effective amount of fluocinolone at or near a target site, one can reduce, prevent or treat inflammation and pain and autoimmune disorders. In various embodiments, fluocinolone formulations may be provided within biodegradable polymers to reduce, prevent or treat sciatic pain and/or inflammation. In various embodiments, prevent transplant rejection for at least twenty-five days. In some embodiments, the pain relief can be for at least fifty days, at least one hundred days, at least one hundred and thirty-five days or at least one hundred and eighty days.
摘要翻译： 提供有效的疼痛和炎症治疗。 通过在靶位点附近施用有效量的氟轻松，可以减少，预防或治疗炎症和疼痛以及自身免疫性疾病。 在各种实施方案中，可以在可生物降解的聚合物内提供氟轻松制剂以减少，预防或治疗坐骨神经痛和/或炎症。 在各种实施方案中，防止移植排斥至少二十五天。 在一些实施方案中，疼痛缓解可以是至少五十天，至少一百天，至少一百三十五天或至少一百八十天。
-
公开(公告)号：US08946277B2
公开(公告)日：2015-02-03
申请号：US12420197
申请日：2009-04-08
申请人： John Myers Zanella , Christopher M. Hobot , Danielle L. Biggs , Katara Shaw , Phillip Edward McDonald , Vanja Margareta King , William F. McKay , Kathy L. Remsen
发明人： John Myers Zanella , Christopher M. Hobot , Danielle L. Biggs , Katara Shaw , Phillip Edward McDonald , Vanja Margareta King , William F. McKay , Kathy L. Remsen
IPC分类号： A01N43/00 , A61K31/33 , A01N43/50 , A61K31/415 , A61K31/4162 , A61K9/00 , A61K9/20 , A61K47/34
CPC分类号： A61K31/4168 , A61K9/0024 , A61K9/204 , A61K31/4162 , A61K47/34
摘要： Effective treatments of pain for extended periods of time are provided. Through the administration of an effective amount of clonidine at or near a target site, one can relieve pain caused by diverse sources, including but not limited to spinal disc herniation (i.e. sciatica), spondilothesis, stenosis, discogenic back pain and joint pain, as well as pain that is incidental to surgery. When appropriate formulations are provided within biodegradable polymers, this relief can be continued for at least three days. In some embodiments, the relief can be for at least twenty-five days, at least fifty days, at least one hundred days, at least one hundred and thirty-five days or at least one hundred and eighty days.
摘要翻译： 提供长时间有效的疼痛治疗。 通过在目标部位处或附近施用有效量的可乐定，可以减轻由多种来源引起的疼痛，包括但不限于脊椎椎间盘突出症（即坐骨神经痛），脊椎脱位，狭窄，椎间盘背痛和关节疼痛，如 以及手术附带的疼痛。 当在可生物降解的聚合物中提供适当的制剂时，这种缓解可以持续至少三天。 在一些实施方案中，缓解可以是至少二十五天，至少五十天，至少一百天，至少一百三十五天或至少一百八十天。
-
公开(公告)号：US20090264478A1
公开(公告)日：2009-10-22
申请号：US12105375
申请日：2008-04-18
申请人： Stephen M. Cox , Christopher M. Hobot , John M. Zanella , Vanja M. King , William F. McKay , Kathy L. Remsen
发明人： Stephen M. Cox , Christopher M. Hobot , John M. Zanella , Vanja M. King , William F. McKay , Kathy L. Remsen
IPC分类号： A61K31/4402 , A61P29/00
CPC分类号： A61K31/635 , A61K9/0024 , A61K47/34
摘要： Effective treatments of acute pain and/or inflammation for extended periods of time are provided. Through the administration of an effective amount of sulfasalazine at or near a target site, one can relieve pain caused by diverse sources, including but not limited to spinal disc herniation (i.e. sciatica), spondilothesis, stenosis, discogenic back pain and joint pain as well as pain that is incidental to surgery. When appropriate formulations are provided within biodegradable polymers, this relief can be continued for at least three days. In some embodiments, the relief can be for at least twenty-five days, at least fifty days, at least one hundred days, at least one hundred and thirty-five days or at least one hundred and eighty days.
摘要翻译： 提供了长时间的急性疼痛和/或炎症的有效治疗。 通过在目标部位或其附近施用有效量的柳氮磺吡啶可以减轻由不同来源引起的疼痛，包括但不限于椎间盘突出症（即坐骨神经痛），脊椎脱位，狭窄，椎间盘背痛和关节疼痛 作为手术附带的疼痛。 当在可生物降解的聚合物中提供适当的制剂时，这种缓解可以持续至少三天。 在一些实施方案中，缓解可以是至少二十五天，至少五十天，至少一百天，至少一百三十五天或至少一百八十天。
-
公开(公告)号：US20090264531A1
公开(公告)日：2009-10-22
申请号：US12413236
申请日：2009-03-27
申请人： John M. Zanella , Vanja M. King , Christopher M. Hobot , S. Mark Cox , Danielle Biggs , Katara Shaw , William F. McKay , Kathy L. Remsen
发明人： John M. Zanella , Vanja M. King , Christopher M. Hobot , S. Mark Cox , Danielle Biggs , Katara Shaw , William F. McKay , Kathy L. Remsen
IPC分类号： A61K31/192 , A61P25/00 , A61P29/00
CPC分类号： A61K31/255 , A61K9/0024 , A61K9/204
摘要： Effective treatments of pain and/or inflammation for extended periods of time are provided. Through the administration of an effective amount of sulindac or a pharmaceutically acceptable salt thereof at or near a target site, one can relieve pain and/or inflammation caused by diverse sources, including but not limited to spinal disc herniation (i.e. sciatica), spondilothesis, stenosis, discongenic back pain and joint pain, as well as pain that is incidental to surgery. When appropriate formulations are provided within biodegradable polymers, this relief can be continued for at least three days, at least twenty-five days. In some embodiments, the relief can be for at least fifty days, at least one hundred days, at least one hundred and thirty-five days or at least one hundred and eighty days.
摘要翻译： 提供了长时间疼痛和/或炎症的有效治疗。 通过在目标部位处或附近施用有效量的舒林酸或其药学上可接受的盐，可以减轻由不同来源引起的疼痛和/或炎症，包括但不限于脊椎椎间盘突出症（即坐骨神经痛），脊椎脱位， 狭窄，恶性背痛和关节疼痛以及手术附带的疼痛。 当在可生物降解的聚合物中提供适当的制剂时，这种缓解可以持续至少三天，至少二十五天。 在一些实施例中，浮雕可以是至少五十天，至少一百天，至少一百三十五天或至少一百八十天。
-
公开(公告)号：US20090264490A1
公开(公告)日：2009-10-22
申请号：US12420197
申请日：2009-04-08
申请人： John Myers ZANELLA , Christopher M. Hobot , Danielle L. Biggs , Katara Shaw , Phillip Edward McDonald , Vanja Margareta King , William F. McKay , Kathy L. Remsen
发明人： John Myers ZANELLA , Christopher M. Hobot , Danielle L. Biggs , Katara Shaw , Phillip Edward McDonald , Vanja Margareta King , William F. McKay , Kathy L. Remsen
IPC分类号： A61K31/4168 , A61P25/00
CPC分类号： A61K31/4168 , A61K9/0024 , A61K9/204 , A61K31/4162 , A61K47/34
摘要： Effective treatments of pain for extended periods of time are provided. Through the administration of an effective amount of clonidine at or near a target site, one can relieve pain caused by diverse sources, including but not limited to spinal disc herniation (i.e. sciatica), spondilothesis, stenosis, discogenic back pain and joint pain, as well as pain that is incidental to surgery. When appropriate formulations are provided within biodegradable polymers, this relief can be continued for at least three days. In some embodiments, the relief can be for at least twenty-five days, at least fifty days, at least one hundred days, at least one hundred and thirty-five days or at least one hundred and eighty days.
摘要翻译： 提供长时间有效的疼痛治疗。 通过在目标部位处或附近施用有效量的可乐定，可以减轻由多种来源引起的疼痛，包括但不限于脊椎椎间盘突出症（即坐骨神经痛），脊椎脱位，狭窄，椎间盘背痛和关节疼痛，如 以及手术附带的疼痛。 当在可生物降解的聚合物中提供适当的制剂时，这种缓解可以持续至少三天。 在一些实施方案中，缓解可以是至少二十五天，至少五十天，至少一百天，至少一百三十五天或至少一百八十天。
-
公开(公告)号：US08557273B2
公开(公告)日：2013-10-15
申请号：US12410151
申请日：2009-03-24
CPC分类号： A61L31/16 , A61K9/0024 , A61K9/1688 , A61K31/4162 , A61K47/34 , A61L27/18 , A61L27/54 , A61L31/06 , A61L2300/204 , A61L2300/602 , A61L2300/604 , A61L2300/622 , A61L2300/63 , C08L67/04
摘要： The implant design is a drug loaded polymer device, such as a rod, designed to control the release of a biologically active agent, such as clonidine or its derivatives, such as clonidine HCl for a prolonged period of time, such as 2 months, 3 months, 4 months, and even 4.5 months. The polymer is preferably a biodegradable polymer, such as poly(lactide-co-glycolide) or polylactic acid/polylactide. The challenge in using the HCl salt forms of drugs such as clonidine, is controlling the release of the highly water soluble drug for up to 4.5 months. It has been found that by controlling the particle size distribution of the drug powder, the drug distribution within the polymer matrix is more uniform and can be controlled. Therefore, the large aggregates, which cause rapid drug release can be eliminated.
-
-
-
-
-
-
-
-
搜索结果
9 条记录 (耗时 0.031 秒)
